Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
HR7432 Sickle Cell Disease Comprehensive Care Act; Social Security Disability Insurance Reform; Sickle Cell Disease - comprehensive care and cell and gene therapy model
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
HR7432 Sickle Cell Disease Comprehensive Care Act; Social Security Disability Insurance Reform; Sickle Cell Disease - comprehensive care and cell and gene therapy model
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · second_quarter · Q2
FY25 funding for TB programs
USAID Tuberculosis program reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
HR7432 Sickle Cell Disease Comprehensive Care Act; Social Security Disability Insurance Reform; Sickle Cell Disease - comprehensive care and cell and gene therapy model
Liver Illness Visibility, Education, and Research Act of 2024
Client: AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Hepatitis C elimination; HR 8601, the Liver Illness Visibility, Education and Research Act
Pay PCPs Act of 2024
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Medicare Physician Payment Reform; S4338, Pay PCP's Act
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Sickle Cell Disease Comprehensive Care Act
Client: AMERICAN SOCIETY OF HEMATOLOGY · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
ARPA–H Act
Client: AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
ARPA-H authorization, including the ARPA-H Act (HR 5585)
ARPA–H Act
Client: AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
ARPA-H authorization, including the ARPA-H Act (HR 5585)
ARPA–H Act
Client: AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
ARPA-H authorization, including the ARPA-H Act (HR 5585)
2024 · second_quarter · Q2
FY25 Appropriations and language for CDC and NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · second_quarter · Q2
HR7432 Sickle Cell Disease Comprehensive Care Act; Social Security Disability Insurance Reform; Sickle Cell Disease - comprehensive care and cell and gene therapy model
Medicare Physician Payment Reform; S4338, Pay PCP's Act
FY2025 Appropriations for NIH and CDC Sickle Cell Disease Data Collection Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · second_quarter · Q2
Hepatitis C elimination; HR 8601, the Liver Illness Visibility, Education and Research Act
FY2025 Appropriations for NIH, CDC Division of Viral Hepatitis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · first_quarter · Q1
FY25 funding for TB programs
USAID Tuberculosis program reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · first_quarter · 1A
HR7432 Sickle Cell Disease Comprehensive Care Act; Social Security Disability Insurance Reform; Sickle Cell Disease - comprehensive care and cell and gene therapy model
FY2025 Appropriations for NIH and CDC Sickle Cell Disease Data Collection Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN SOCIETY FOR MICROBIOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · first_quarter · Q1
FY25 Appropriations and language for CDC and NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · first_quarter · Q1
HR7432 Sickle Cell Disease Comprehensive Care Act; Social Security Disability Insurance Reform; Sickle Cell Disease - comprehensive care and cell and gene therapy model
FY2025 Appropriations for NIH and CDC Sickle Cell Disease Data Collection Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2024 · first_quarter · Q1
FY2025 Appropriations for NIH, CDC Division of Viral Hepatitis
Hepatitis C elimination
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · fourth_quarter · Q4
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · fourth_quarter · Q4
Hepatitis C elimination
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · fourth_quarter · Q4
USAID Tuberculosis program reauthorization
FY24 funding for TB programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY FOR MICROBIOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · fourth_quarter · Q4
FY24 Appropriations and language for CDC and NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · third_quarter · Q3
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · third_quarter · Q3
Hepatitis C elimination
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · third_quarter · Q3
FY24 funding for TB programs
USAID Tuberculosis program reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY FOR MICROBIOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · third_quarter · Q3
FY24 Appropriations and language for CDC and NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · second_quarter · Q2
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN UROLOGICAL ASSOCIATION via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · second_quarter · Q2
FY24 Department of Defense Appropriations; FY24 Labor HHS Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · second_quarter · Q2
Hepatitis C elimination
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · second_quarter · Q2
USAID Tuberculosis program reauthorization
FY24 funding for TB programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY FOR MICROBIOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · second_quarter · Q2
FY24 Appropriations and language for CDC and NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · first_quarter · Q1
USAID Tuberculosis program reauthorization
FY24 funding for TB programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEMATOLOGY via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · first_quarter · Q1
FY24 Funding for the NIH and the CDC Sickle Cell Data Collection Program
Sickle Cell Disease Comprehensive Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN UROLOGICAL ASSOCIATION via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · first_quarter · Q1
FY24 Department of Defense Appropriations; FY24 Labor HHS Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · first_quarter · Q1
Hepatitis C elimination
FY24 Labor HHS Report Language re: a liver disease strategy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN STATISTICAL ASSOCIATION via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2023 · first_quarter · RR
FY24, Labor, Health & Human Services Education Appropriations Act; HR/S no bill number Reauthorization of the Education Sciences Reform Act
FY24, Labor, Health & Human Services Education Appropriations Act; HR/S no bill number Reauthorization of the Education Sciences Reform Act
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2022 · fourth_quarter · Q4
FY23 Appropriations and report language for TB programs at DoD, HHS and USAID
USAID Tuberculosis program reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2022 · fourth_quarter · Q4
ARPA-H authorization, including the ARPA-H Act (HR 5585)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2022 · third_quarter · Q3
ARPA-H authorization, including the ARPA-H Act (HR 5585)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (TB ALLIANCE) via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2022 · third_quarter · Q3
FY23 Appropriations and report language for TB programs at DoD, HHS and USAID
USAID Tuberculosis program reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN UROLOGICAL ASSOCIATION via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2022 · second_quarter · Q2
FY23 Defense Appropriations bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSN FOR THE STUDY OF LIVER DISEASES via CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2022 · second_quarter · Q2
ARPA-H authorization, including the ARPA-H Act (HR 5585)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE